Stockholders Approve Reverse Stock Split Authority for Xilio Therapeutics

summarizeSummary

Xilio Therapeutics stockholders approved a reverse stock split, granting the board discretion to implement a ratio between 1-for-2 and 1-for-30, a key step for Nasdaq compliance.

check_boxKey Events

• Stockholders Approve Reverse Stock Split

  At a special meeting on February 23, 2026, stockholders approved an amendment to the company's certificate of incorporation to effect a reverse stock split.

• Board Granted Discretionary Authority

  The board of directors now has the sole discretion to determine the exact ratio (between 1-for-2 and 1-for-30) and timing of the reverse stock split without further stockholder approval.

• Follows Prior Proxy Filings

  This approval finalizes the proposal previously outlined in the definitive proxy statement filed on January 26, 2026, which sought stockholder authorization for this action.

auto_awesomeAnalysis

This 8-K reports that Xilio Therapeutics' stockholders have approved the board's authority to implement a reverse stock split at a ratio between 1-for-2 and 1-for-30. This approval is a critical step for the company, likely aimed at increasing its per-share price to meet Nasdaq's minimum bid requirements and avoid potential delisting. The board now has the discretion to determine the exact ratio and timing of the split. This follows previous proxy filings seeking this approval and comes amidst recent capital raising activities, including a public offering of pre-funded warrants and an ATM program.